What tumor-related factors help in deciding between BRAF/MEKi vs ICI in stage IV BRAF mutant melanoma patients?
Community PollStarted
Do you start treatment with BRAF inhibition or immunotherapy in Stage 4 BRAF mutated patients?
11 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University Comprehensive Cancer Center
Answered on
Any patient who has a contraindication to ICI (autoimmune disease, transplant, etc...), I start with BRAF inhibitors, unless the patient is eligible for a clinical trial.
Otherwise, I start with ICI, given the latest results of ECOG EA6134. Whether I choose combo with ipi and single agent PD1 inhibitor or single agent PD1 inhibitor depends on the melanoma prognosis and the comorbidities of the patient.
Join for free or sign in to see the full answer